211 related articles for article (PubMed ID: 24950357)
1. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.
Pedersen GK; Höschler K; Øie Solbak SM; Bredholt G; Pathirana RD; Afsar A; Breakwell L; Nøstbakken JK; Raae AJ; Brokstad KA; Sjursen H; Zambon M; Cox RJ
Vaccine; 2014 Jul; 32(35):4550-4557. PubMed ID: 24950357
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
5. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.
Khurana S; Wu J; Dimitrova M; King LR; Manischewitz J; Graham BS; Ledgerwood JE; Golding H
J Infect Dis; 2013 Aug; 208(3):413-7. PubMed ID: 23633404
[TBL] [Abstract][Full Text] [Related]
6. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
7. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
8. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.
Khurana S; Coyle EM; Manischewitz J; King LR; Ishioka G; Alexander J; Smith J; Gurwith M; Golding H
PLoS One; 2015; 10(1):e0115476. PubMed ID: 25629161
[TBL] [Abstract][Full Text] [Related]
9. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
11. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
[TBL] [Abstract][Full Text] [Related]
12. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.
Santiago FW; Fitzgerald T; Treanor JJ; Topham DJ
Vaccine; 2011 Nov; 29(48):8888-97. PubMed ID: 21963871
[TBL] [Abstract][Full Text] [Related]
14. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
Front Immunol; 2019; 10():2006. PubMed ID: 31552018
[TBL] [Abstract][Full Text] [Related]
15. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
[TBL] [Abstract][Full Text] [Related]
16. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
[TBL] [Abstract][Full Text] [Related]
17. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.
Verma S; Dimitrova M; Munjal A; Fontana J; Crevar CJ; Carter DM; Ross TM; Khurana S; Golding H
J Virol; 2012 Nov; 86(22):12283-93. PubMed ID: 22951833
[TBL] [Abstract][Full Text] [Related]
18. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
19. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
[TBL] [Abstract][Full Text] [Related]
20. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
